<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00504972</url>
  </required_header>
  <id_info>
    <org_study_id>0608008669</org_study_id>
    <nct_id>NCT00504972</nct_id>
  </id_info>
  <brief_title>Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies</brief_title>
  <official_title>Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous experience with antibody therapy in both NHL and CLL warrants further exploration of&#xD;
      new antibody treatments for these diseases.&#xD;
&#xD;
      Immunomedics has developed hLL1 (previously designated EPB-1), which is a CDR-grafted, fully&#xD;
      humanized monoclonal antibody specifically targeting CD74.38 The human IgG1 backbone for hLL1&#xD;
      is the same as hLL2 (epratuzumab), a monoclonal antibody whose safety has been demonstrated&#xD;
      in clinical trials of patients with B-cell malignancies and autoimmune disorders.&#xD;
&#xD;
      This is a Phase I, open-label, study conducted in patients with recurrent non-Hodgkin's&#xD;
      lymphoma (NHL) or chronic lymphocytic leukemia (CLL) who have progressed after at least one&#xD;
      prior standard treatment. All patients will receive hLL1 administered intravenously once&#xD;
      daily Monday through Friday of each of 2 consecutive weeks (10 total doses.) Patients will be&#xD;
      assigned to a cohort for hLL1 treatment dose assignment (escalating doses of hLL1 per&#xD;
      statistical plan) in order to determine the maximum tolerated dose (MTD) for this&#xD;
      administration schedule.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">October 7, 2015</completion_date>
  <primary_completion_date type="Actual">April 1, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the toxicity profile and maximum tolerated dose (MTD) of hLL1 when administered to patients with recurrent non-Hodgkin's lymphoma and chronic lymphocytic leukemia</measure>
    <time_frame>duration of study</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Study Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This study is a single arm study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hLL1</intervention_name>
    <description>hLL1 administered intravenously once daily Monday through Friday for 2 consecutive weeks (10 total doses) at one of 4 planned dose levels: 1.5, 4, 6 or 8 mg/kg.</description>
    <arm_group_label>Study Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of recurrent B cell non-Hodgkin's lymphoma or&#xD;
             diagnosis of recurrent chronic lymphocytic leukemia&#xD;
&#xD;
          -  Patient has received at least one prior treatment with standard chemotherapy and at&#xD;
             least one prior treatment with rituximab (negative HAHA test required if received&#xD;
             prior humanized antibody treatment)&#xD;
&#xD;
          -  Patient has not received anti-cancer therapy within 28 days of treatment unless&#xD;
             disease progression has been demonstrated and toxicities from prior therapy have&#xD;
             resolved&#xD;
&#xD;
          -  Available tumor tissue (lymph node/mass, blood or bone marrow) for correlative&#xD;
             analyses (paraffin or frozen, recent or archived)&#xD;
&#xD;
          -  Measurable disease as defined by a tumor mass &gt; 1.5 cm in one dimension or WBC &gt; 5,000&#xD;
             (CLL patients)&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Patient has KPS &gt; 50%&#xD;
&#xD;
          -  Absolute granulocyte count &gt; 1000 cells/mm3&#xD;
&#xD;
          -  Platelet count &gt; 50,000 cells/mm3&#xD;
&#xD;
          -  Creatinine &lt; 2.0 x ULN&#xD;
&#xD;
          -  Total bilirubin &lt; 2.0 x ULN&#xD;
&#xD;
          -  Patient agrees to use birth control if of reproductive potential&#xD;
&#xD;
          -  Patient has signed IRB-approved informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known central nervous system (CNS) involvement by lymphoma&#xD;
&#xD;
          -  Known HIV disease&#xD;
&#xD;
          -  Patient is pregnant or nursing&#xD;
&#xD;
          -  Patient is receiving other investigational drugs&#xD;
&#xD;
          -  Known serum human anti-human antibodies (HAHA)&#xD;
&#xD;
          -  Estimated life expectancy of &lt; 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John P Leonard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>July 19, 2007</study_first_submitted>
  <study_first_submitted_qc>July 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2007</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

